Hostname: page-component-cd9895bd7-jn8rn Total loading time: 0 Render date: 2024-12-25T03:05:47.488Z Has data issue: false hasContentIssue false
  • English
  • Français

Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels

Published online by Cambridge University Press:  16 April 2020

M.C. Mauri ,
V. Laini ,
L. Boscati ,
R. Rudelli ,
V. Salvi ,
R. Orlandi  and
P. Papa
M.C. Mauri*
Affiliation:
Department of Clinical Psychiatry, Clinical Neuropsychopharmacology Unit, University of Milan, IRCCS Ospedale Maggiore, Via F. Sforza35, 20122Milan, Italy
V. Laini
Affiliation:
Department of Clinical Psychiatry, Clinical Neuropsychopharmacology Unit, University of Milan, IRCCS Ospedale Maggiore, Via F. Sforza35, 20122Milan, Italy
L. Boscati
Affiliation:
Department of Clinical Psychiatry, Clinical Neuropsychopharmacology Unit, University of Milan, IRCCS Ospedale Maggiore, Via F. Sforza35, 20122Milan, Italy
R. Rudelli
Affiliation:
Department of Clinical Psychiatry, Clinical Neuropsychopharmacology Unit, University of Milan, IRCCS Ospedale Maggiore, Via F. Sforza35, 20122Milan, Italy
V. Salvi
Affiliation:
Department of Clinical Psychiatry, Clinical Neuropsychopharmacology Unit, University of Milan, IRCCS Ospedale Maggiore, Via F. Sforza35, 20122Milan, Italy
R. Orlandi
Affiliation:
Department of Toxicology, IRCCS Policlinico S. Matteo, Pavia, Italy
P. Papa
Affiliation:
Department of Toxicology, IRCCS Policlinico S. Matteo, Pavia, Italy
*
*Correspondence and reprints. E-mail address: [email protected] (M.C. Mauri).
Get access

Abstract

Twenty-four chronic schizophrenic outpatients with a mean age of 37.21 years ± 9.96 SD were treated with risperidone (RSP) at the dosage of 2–9 mg/die (mean 4.46 mg/die ± 1.30 SD, mean 0.06 mg/kg ± 0.01 SD) for a year.

Clinical evaluation was assessed with the Brief Psychiatric Rating Scale (BPRS), Positive and Negative Symptoms Scale (PANSS), Extrapyramidal Side Effects Rating Scale (EPSE) and a checklist for Anticholinergic Side Effects (ACS) at T0, then after 1 (T1), 2 (T2), 3 (T3), 6 (T6), 9 (T9) and 12 (T12) months. RSP and 9-hydroxy-risperidone (9OH-RSP) plasma levels were determined at T12 by the HPLC method. BPRS and PANSS mean values showed a significant improvement during the study. No correlation between RSP dosage (mg/kg) and RSP, 9OH-RSP plasma levels or active moiety resulted. A positive correlation between age and active moiety was observed. A positive correlation between RSP and 9OH-RSP plasma levels was observed. A curvilinear relationship between active moiety and PANSS improvement (%) was observed. Patients with the higher PANSS amelioration showed RSP + 9OH-RSP plasma levels ranging from 15 to 30 ng/mL. RSP seems to be quite an effective drug. It seems, however, difficult to devise appropriate dose schedules and plasma level determination seems to be necessary in some cases.

Type
Original article
Information
European Psychiatry , Volume 16 , Issue 1 , February 2001 , pp. 57 - 63
Copyright
Copyright © Éditions scientifiques et médicales Elsevier SAS.

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association. DSM IV diagnostic and statistical manual of mental disorders Washington, DC: APA Press; 1994.Google Scholar
Anderson, CTrue, JEreshefsky, LMiller, A.Risperidone clinical efficacy: role of the metabolite 9-hydroxy-risperidone. Psychopharmacol Bull 30 Suppl 1: 8888.Google Scholar
Bondolfi, GDufour, HPatris, MMay, JPBilleter, UEap, CB.Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. Am J Psychiatry 1998; 155: 499–504.CrossRefGoogle ScholarPubMed
Carman, JPeuskens, JVangeneugden, A.Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int Clin Psychopharmacol 1995; 10: 207–213.CrossRefGoogle ScholarPubMed
Chouinard, GJones, BRemington, GBloom, DAddington, DMacEwan, GW, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13: 25–40.CrossRefGoogle ScholarPubMed
Claus, ABollen, JDeCuyper, HEneman, MMalfroid, MPeuskens, J et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992; 20: 295–305.CrossRefGoogle Scholar
Conley, RRLove, RCKelly, DLBartko, JJ.Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. Am J Psychiatry 1999; 156: 863–868.CrossRefGoogle ScholarPubMed
Curry, SH.Commentary: the strategy and value of neuroleptic drug monitoring. J Clin Psychopharmacol 1985; 5: 263–271.CrossRefGoogle Scholar
Diaourta-Tsitouridou, MChristodoulakis, TTsitouridis, S.Efficacy and tolerability of risperidone in drug-naive schizophrenic and schizoaffective patients. Eur Neuropsychopharmacol 1997; 7 Suppl 2: 200200.CrossRefGoogle Scholar
Draper, NSmith, H.Applied regression analysis. 2nd ed. New York: Wiley; 1981.Google Scholar
Draper, NSmith, H.Applied regression analysis. 2nd ed. New York: Wiley; 1981.Google Scholar
Ereshefsky, LLacombe, S.Pharmacological profile of risperidone. Can J Psychiatry 1993; 38 Suppl 3: 80–88.Google ScholarPubMed
Fleischhacker, WWHummer, M.Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes. Drugs 1997; 53: 915–929.CrossRefGoogle ScholarPubMed
Foster, RHGoa, KL.Risperidone. A pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics 1998; 14: 97–133.CrossRefGoogle Scholar
Gelders, YGHeylen, S.LEVanden Bussche, GReyntjens, AJJanssen, P.AJ.Pilot clinical investigation of risperidone in the treatment of psychotic patients. Pharmacopsychiatry 1990; 23: 206–211.CrossRefGoogle ScholarPubMed
Grant, SFitton, A.Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs 1994; 48: 253–273.CrossRefGoogle ScholarPubMed
Heykants, JHuang, MLMannens, GMeuldermans, WSnoeck, EVan Beijsterveldt, L et al. The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 1994; 55 Suppl 5: 13–17.Google ScholarPubMed
Kay, SRFiszbein, AOpler, LA.The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophr Bull 1987; 13: 261–276.CrossRefGoogle Scholar
Lindström, EEriksson, BHellgren, AVon Knorring, LEberhard, G.Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin Ther 1995; 17: 402–412.CrossRefGoogle ScholarPubMed
Luchins, DJKlass, DHanrahan, PMalan, RHarris, J.Alteration in the recommended dosing schedule for risperidone. Am J Psychiatry 1998; 155: 365–366.CrossRefGoogle ScholarPubMed
Mannens, GHuang, MLMeuldermans, WHendrickx, JWoestenborghs, RHeykants, J.Absorption, metabolism and excretion of risperidone in humans. Drug Metab Dispos 1993; 21: 1134–1141.Google ScholarPubMed
Marder, SRMeibach, RC.Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825–835.Google ScholarPubMed
Mauri, MCLaini, VScalvini, MBoscati, LSteinhilber, C.PCInvernizzi, G.Risperidone and 9OH-risperidone plasma levels in schizophrenic patents. Int J Neuropsychopharmacol 1999; 2 Suppl 1: 100100.Google Scholar
Mertens, C.Long-term treatment of chronic schizophrenic patients with risperidone. Schizophr Res 1990; 3: 4848.CrossRefGoogle Scholar
Miller, CHMohr, FUmbricht, DWoerner, MFleischhacker, WWLieberman, JA.The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone and conventional antipsychotics. J Clin Psychiatry 1998; 58: 69–75.CrossRefGoogle Scholar
Möller, HJGagiano, CAAddington, DEVon Knorring, LTorres-Plank, JFGaussares, C.Long-term treatment of chronic schizophrenia with risperidone: an open-label multicenter study of 386 patients. Int Clin Psychopharmacol 1998; 13: 99–106.CrossRefGoogle ScholarPubMed
Nair, N.PV.The Risperidone Study Group. Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia. J Clin Psychopharmacol 1998; 18: 103–110.CrossRefGoogle Scholar
Nyberg, SEriksson, BOxenstierna, GHalldin, CFarde, L.Suggested minimal effective dose of risperidone based on PET-measured D2 and 5HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry 1999; 156: 869–875.CrossRefGoogle Scholar
Overall, JGorham, D.Brief Psychiatric Rating Scale. Psychol Rep 1962; 10: 799–812.CrossRefGoogle Scholar
Price, MCHoffman, DW.Therapeutic drug monitoring of risperidone and 9-hydroxy-risperidone in serum with solid phase extraction and high-performance liquid cromatography. Ther Drug Monit 1997; 19: 333–337.CrossRefGoogle Scholar
Reilly, TMHeylen, S.LE.Guidelines for the practical use of risperidone In: Kane, JMMoller, HJAwouters, F, Serotonin in antipsychotic treatment. Mechanism and clinical practice New York: Marcel Dekker Inc; 1996. p. 357–368.Google Scholar
Remington, GJ.Clinical considerations in the use of risperidone. Can J Psychiatry 1993; 38 Suppl 3: 96–100.Google ScholarPubMed
Simpson, RMAngus, J.SW.A rating scale for Extrapyramidal Side Effects. Acta Psychiatr Scand 1970; 212: 11–19.CrossRefGoogle ScholarPubMed
Snoeck, EVan Peer, ASack, MHorton, MMannens, GWoestenborghs, Ret al. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology 1995; 122: 223–229.CrossRefGoogle ScholarPubMed
Van Beijsterveldt, LGeerts, RLeysen, JMegens, AVan den Eynde, HMeuldermans, Wet al. The regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacology 1993; 114: 53–62.CrossRefGoogle Scholar
Van Peer, AVMeuldermans, WWoestenborghs, RHeykants, JClinical pharmacokinetics of risperidone. In: Kane, JMMoller, HJAwouters, F, Serotonin in antipsychotic treatment. Mechanism and clinical practice. New York: Marcel Dekker Inc; 1996. p. 277–291.Google Scholar
Weiden, PAquila, RStandard, J.Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry 1996; 57: 53–60.Google Scholar
Wirshing, DAMarshall, BDGreen, MFMintz, JMarder, SRWirshing, WC.Risperidone in treatment-refractory schizophrenia. Am J Psychiatry 1999; 156: 1374–1379.Google ScholarPubMed
Woestenborghs, RLorreyne, WVan Rompaey, FHeykants, J.Determination of risperidone and 9-hydroxy risperidone in plasma, urine and animal tissues by high performance liquid chromatography. J Chromatography 1992; 583: 223–230.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.